AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00063362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
Study NCT00063362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
Study NCT00063362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex
Description: Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
Study NCT00851760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive surgery
Description: Consecutive surgery for epiretinal macular membrane and cataract extraction
Study NCT00529191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One out of three subjects will receive a placebo.
Study NCT04964687 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study NCT01519830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron carboxymaltose (Ferinject)
Description: Intravenous iron
Study NCT01519830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution
Study NCT04273386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation
Description: The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
Study NCT03050424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: Ferric Carboxymaltose injectable Product
Study NCT03050424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9%
Study NCT05006131 — intervention group
Intervention type: OTHER
Intervention: Screening for pancreatic cancer
Description: Screening for pancreatic cancer using EUS or MRI
Study NCT00870129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI and advanced MRI sequences
Description: This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
Study NCT02043392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnamosis
Description: Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
Study NCT01476501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
Study NCT02933892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Catheterization
Description: Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
Study NCT03583398 — intervention group
Intervention type: PROCEDURE
Intervention: transcatheter aortic valve implantation, surgical aortic valve replacement
Description: Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
Study NCT00654186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: 25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
Study NCT04872231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole Inhalation Powder
Description: PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID.
Study NCT04872231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses.
Study NCT01586039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light
Description: We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
Study NCT01586039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light
Description: We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
Study NCT02610881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid (IFA)
Description: 1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
Study NCT02610881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders (MNP)
Description: One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base
Study NCT02610881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iron Plus Strategy Counseling
Description: Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
Study NCT04269122 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT01620840 — intervention group
Intervention type: DRUG
Intervention: Lacosamide 10mg/ml
Description: intravenous administration up to 10 days
Study NCT03680144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-MRI (DSC-MRI)
Description: Undergo DSC-MRI
Study NCT03680144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo diagnostic MRI
Study NCT01185158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839 (IRESSA)
Description: ZD1839: 250mg/day po or via g-tube Q 24 hours
Study NCT00862563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
Study NCT00862563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
Study NCT00862563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
Study NCT00862563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
Study NCT03914105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without music
Description: The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration.
Study NCT03914105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With music
Description: The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration.
Study NCT01483820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
Study NCT03682276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody given as an immunotherapy
Study NCT03682276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a monoclonal antibody given as an immunotherapy
Study NCT01780350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResQGARD ITD
Description: Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
Study NCT04599751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair removal treatment
Description: Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
Study NCT02946424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: 12 month course of daily placebo
Study NCT02946424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 12 month course of daily simvastatin
Study NCT02985749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
Study NCT02582190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine group
Description: antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
Study NCT00310115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smoking Prevention Usual Care
Description: Usual care of self-help materials and advice for staying cigarette free
Study NCT00851760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined surgery
Description: Combined surgery for epiretinal macular membrane and cataract extraction
Study NCT00310115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling Intervention
Description: 6 x 30 minute counseling sessions over the telephone
Study NCT00310115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling Intervention
Description: 2 in-person counseling sessions
Study NCT02770690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethyl chloride spray
Description: apply the spray for 5 seconds on the dorsal hand before propofol iv injection
Study NCT02770690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: apply lidocaine under the tourniquet state before propofol iv injection
Study NCT02770690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: apply normal saline before propofol iv injection
Study NCT02024048 — intervention group
Intervention type: OTHER
Intervention: OCT
Description: Optical coherence tomography in enhanced depth imaging mode
Study NCT04852133 — intervention group
Intervention type: OTHER
Intervention: Burn subjects
Description: see eligibility criteria
Study NCT00325182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Study NCT00325182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Historical controls
Study NCT00721162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
Study NCT00585741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-FLT PET
Description: Imaging with 18F-FLT PET
Study NCT01889940 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training for professionals (Spinal Cord Injury Unit staff).
Description: Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period.
Study NCT03203278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based exercise programme
Description: Aerobic, resistance and balance exercises
Study NCT03387644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin (PG)
Description: Pregabalin 150 mg one hour before the procedure as premedication.
Study NCT03387644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo (C)
Description: Placebo tablets one hour before the procedure as premedication.
Study NCT00814879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg BID
Study NCT00814879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg BID
Study NCT00814879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment regimen
Description: N(t)RTI(s) based backbone plus ritonavir boosted PI
Study NCT01343225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atripla
Description: once a day
Study NCT01343225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir ritonavir raltegravir
Description: as directed
Study NCT01753362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Study NCT01753362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00647218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant therapy
Description: Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
Study NCT00647218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
Study NCT01195233 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bioxtra
Description: spray /mouth rinse
Study NCT04633863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial tear MDI - 101
Description: Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
Study NCT03246503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiliCam estimated bilirubin (BCB)
Description: Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
Study NCT00063362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Community Case Management
Description: CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Community Case Management
Description: CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
Study NCT03385135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300 mg for 4 weeks then 600 mg for 4 weeks in the active group
Study NCT03795012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
Study NCT03357380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
Study NCT03357380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.